Total Funding
93
72
Total FundingDebt Financing raised
Growth Score
4 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
92691
Vogenx is a clinical stage drug development company focusing on treatment of diseases associated with dysfunctions in human metabolism
- Steven Delmar: CFO
About the Company
Vogenx is a clinical stage life science and drug development company focused on the development of novel therapeutics for the treatment of important diseases associated with dysfunctions in human metabolism including post bariatric hypoglycemia (PBH), gastroparesis, and obesity.
The lead asset, Mizagliflozin, is an investigational first-in-class,
oral, small molecule drug candidate that reduces postprandial glucose absorption, secretion of insulin, and secretion of gastric inhibitory peptide (GIP). The molecule is being developed by Vogenx for the treatment of PBH and gastroparesis, both debilitating diseases with high unmet medical need in underserved patient populations.
